Journal
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
Volume 13, Issue 3, Pages -Publisher
WILEY
DOI: 10.1002/wnan.1689
Keywords
anticancer therapy; cancer nanotechnology; drug delivery system; drug targeting; EPR effect; nanomedicine; PEGylation; polymer conjugation
Funding
- Associazione Italiana per la Ricerca sul Cancro [IG2017]
- Fondazione per la Ricerca sulla Fibrosi Cistica [9/2018]
Ask authors/readers for more resources
Polymer conjugation is a leading approach in nanotechnology-based drug delivery systems, aiming to improve in vivo behavior and pharmacokinetic activities of active molecules. While conjugation with biotech drugs has achieved clinical use, conjugation with low molecular weight drugs has not yet reached clinical approval due to challenges in achieving selective targeting. Researchers are working towards identifying more sophisticated and biocompatible delivery approaches to enhance drug targeting for successful clinical applications.
Polymer conjugation can be considered one of the leading approaches within the vast field of nanotechnology-based drug delivery systems. In fact, such technology can be exploited for delivering an active molecule, such as a small drug, a protein, or genetic material, or it can be applied to other drug delivery systems as a strategy to improve their in vivo behavior or pharmacokinetic activities such as prolonging the half-life of a drug, conferring stealth properties, providing external stimuli responsiveness, and so on. If on the one hand, polymer conjugation with biotech drug is considered the linchpin of the protein delivery field boasting several products in clinical use, on the other, despite dedicated research, conjugation with low molecular weight drugs has not yet achieved the milestone of the first clinical approval. Some of the primary reasons for this debacle are the difficulties connected to achieving selective targeting to diseased tissue, organs, or cells, which is the main goal not only of polymer conjugation but of all delivery systems of small drugs. In light of the need to achieve better drug targeting, researchers are striving to identify more sophisticated, biocompatible delivery approaches and to open new horizons for drug targeting methodologies leading to successful clinical applications. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available